Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report

Journal of Medical Case Reports

Christof Vulsteke¹  Charlotte Gabriel²  Antoon Lambrecht³  Eva Van Bos⁴  Filip Ameye⁴  Charlotte Soenens⁴  Stefan Huybrechts⁴  Peter Dekuyper⁴  Marjan Waterloos⁴  Anthony Van Baelen⁴ 

[1] Department of Oncology, AZ Maria Middelares, Ghent, Belgium;Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium;Department of Pathology, AZ Maria Middelares, Ghent, Belgium;Department of Radiotherapy, AZ Groeninge, Kortrijk, Belgium;Department of Urology, AZ Maria Middelares, Buitenring-Sint-Denijs 30, 9000, Ghent, Belgium;

关键词: Prostate cancer;    Small cell carcinoma;    Low-dose-rate brachytherapy;    Ionizing radiotherapy;    Chemotherapy;    Immunotherapy;   

DOI  :  10.1186/s13256-020-02523-5

来源: Springer

【 摘 要 】

BackgroundSmall cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy.Case presentationThis report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy.ConclusionLow-dose-rate brachytherapy might be an etiology of small cell prostate cancer.

【 授权许可】

CC BY